Clinical Trials Logo

Clinical Trial Summary

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) .It is the most common neurological disorders affecting young adults.Multiple sclerosis is an autoimmune disease that results in progressive neural degeneration. Cytokines play an important role in the pathogenesis and treatment of MS.


Clinical Trial Description

This research aims to evaluate the effect of aerobic exercises on the immune system anti-inflammatory (IL-10) and pro inflammatory (IL-17) cytokines and its consequences on the functional status in the Multiple Sclerosis patients.

Aerobic exercises are a term to describe planned, structured and repetitive physical activity undertaken over a prolonged period to maintain or improve physical fitness and functional capacity . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04545372
Study type Interventional
Source South Valley University
Contact
Status Completed
Phase N/A
Start date February 2, 2015
Completion date August 6, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03455582 - Cognition Evolution and MRI Markers in PPMS Patients on 2 Years N/A
Active, not recruiting NCT04544449 - A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis Phase 3
Completed NCT06436131 - The Effects of In-phase Bilateral Exercise in People With Progressive Multiple Sclerosis N/A
Recruiting NCT04918225 - Motor Asymmetry in Progressive Multiple Sclerosis Patients
Completed NCT02913157 - Hydroxychloroquine in Primary Progressive Multiple Sclerosis Phase 2
Completed NCT01982942 - Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Phase 2
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Completed NCT05663853 - An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
Completed NCT01194570 - A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Phase 3
Completed NCT02305264 - Imaging of Intracerebral Inflammation in MS N/A
Completed NCT03679468 - Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation N/A
Recruiting NCT05496881 - Exercise Effects in Multiple Sclerosis N/A
Completed NCT02506751 - Open-label Study of Liothyronine in MS Phase 1
Temporarily not available NCT02606929 - Use of Well Known Drugs for New Destination - MS Improvement (MSNT) Phase 0
Completed NCT03424538 - The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients N/A
Recruiting NCT05122559 - Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT02988401 - Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Phase 1/Phase 2
Completed NCT02632591 - Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment Phase 1
Completed NCT01917019 - A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Phase 3
Completed NCT01433497 - Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis Phase 3